These companies have been ranked based on their stock's excess return over the Sensex for a five-year period
With a powerful client base and an all-in-one package, the contract R&D firm Syngene is galloping ahead and now even into manufacturing
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues
The domestic pharma industry, which is already battling the US FDA, has now to contend with regulatory challenges at home
Even as it battles the US FDA, the industry has been caught off-guard by policy changes back home
Mankind Pharma made it big in small towns, but can its magic help it conquer the bigger markets?
Can Sun Pharma’s Dilip Shanghvi work his merger magic on Ranbaxy?
Nephroplus’ Vikram Vuppala’s eight-wheelers can outrun any fancy car
The Piramal group head on how his values have helped him make bold business decisions